In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis

NCT01927120 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Graft-Versus-Host-Disease

Interventions

DRUG: IL-2
DRUG: Tacrolimus
DRUG: Sirolimus

Sponsor

H. Lee Moffitt Cancer Center and Research Institute